1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for individuals in Krakow who are battling with opioid abuse and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to give specific medications to opioid dependent individuals, many that are opioid-based themselves and are addiction. In low enough amounts however, the client does not feel high and also does not have severe cravings and is not experiencing opioid withdrawal. Methadone is the first medication used for this reason, but there are alternative choices to pick from.
Methadone is an opioid and can be taken at an outpatient medical center licensed to administer the med, which is taken on a daily basis in liquid or pill form. The cost of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based drug, and is a pill often taken one day on, one day off. But unlike Methadone that is only be dispensed in well-regulated medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is approximately just under $300 /month for the generic of the medication. There is also a type of buprenorphine that contains the ingredient naloxone, that is a med that reverses the effects of opioids. A person taking this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and is priced about $450 per month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other medications aforementioned it is an opioid blocker and is not an opiate. A person has the choice to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, it prevents a person from feeling high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 a month.
For All Drug and Alcohol Rehabilitation Centers In Krakow, Click Here.
